Working… Menu
Trial record 1 of 2 for:    Recruiting Studies | Interventional Studies | Gastric Cancer | manitoba | Canada
Previous Study | Return to List | Next Study

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03797326
Recruitment Status : Recruiting
First Posted : January 9, 2019
Last Update Posted : September 16, 2021
Eisai Inc.
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : September 17, 2024
Estimated Study Completion Date : September 17, 2024